Systematic screening, risk stratification, and preventive strategies for anthracycline-related cardiotoxicity in pediatric oncology provide opportunities to mitigate or prevent myocardial injury.
What are the risk factors, surveillance indexes, and preventive strategies for anthracycline-related cardiotoxicity in pediatric patients?
Systematic screening and risk stratification are essential to mitigate and prevent cumulative and irreversible anthracycline-induced cardiotoxicity in pediatric cancer survivors.
Anthracyclines have significantly improved the survival of children with malignant tumors, but the associated cardiotoxicity, an effect now under the purview of pediatric cardio-oncology, due to its cumulative and irreversible effects on the heart, limits their clinical application. A systematic screening and risk stratification approach provides the opportunity for early identification and intervention to mitigate, reverse, or prevent myocardial injury, remodeling, and dysfunction associated with anthracyclines. This review summarizes the risk factors, surveillance indexes, and preventive strategies of anthracycline-related cardiotoxicity to improve the safety and efficacy of anthracyclines.
Liu et al. (Mon,) conducted a review in Anthracycline-related cardiotoxicity in children with malignant tumors. Screening, risk stratification, and prevention strategies was evaluated. Systematic screening, risk stratification, and preventive strategies for anthracycline-related cardiotoxicity in pediatric oncology provide opportunities to mitigate or prevent myocardial injury.